The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
LIVDELZI Gilead Sciences Pty Ltd
Product name
LIVDELZI
Sponsor
Accepted date
Jan-2025
Active ingredients
Seladelpar lysine dihydrate
Proposed indication
LIVDELZI is used to treat primary biliary cholangitis in adults, an autoimmune condition which destroys the bile ducts in the liver. LIVDELZI can be used with the first-line treatment ursodeoxycholic acid (UDCA) if UDCA alone isn't effective or by itself if UDCA isn't tolerated.
Application type
A (new medicine)
Publication date
Jan-2025